Johns Hopkins Preliminary Trial Explores Psilocybin for OCD Treatment

A Johns Hopkins preprint study shows promising preliminary results for psilocybin-assisted therapy in treating obsessive-compulsive disorder (OCD), with participants demonstrating improvements compared to a waitlist control group. However, researchers emphasize significant methodological limitations and the occurrence of adverse effects that warrant caution in interpreting these findings. The trial represents an early exploration into psychedelic-assisted treatment for OCD, a condition affecting millions worldwide that often shows treatment resistance. While results are encouraging, larger, more rigorous randomized controlled trials are needed before clinical applications can be considered. Patients with OCD should continue working with mental health professionals on established evidence-based treatments while this research evolves.